Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.

Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
2003 Oct
Bouma M, Nuijen B, Harms R, Rice JR, Nowotnik DP, Stewart DR, Jansen BA, van Zutphen S, Reedijk J, van Steenbergen MJ, Talsma H, Bult A, Beijnen JH.
Drug Dev Ind Pharm. 2003 Oct;29(9):981-95.
PubMed
Department of Pharmacy and Pharmacology, Slotervaart Hospital/ The Netherlands Cancer Institute, Amsterdam, The Netherlands. m.bouma@wza.nl
AP 5280 is a novel polymer-conjugated platinum anticancer agent showing promising in vitro and in vivo activity against solid tumors. The aim of this study was to develop a parenteral pharmaceutical dosage form for phase I clinical trials. AP 5280 drug substance was characterized by using a wide range of analytical techniques and showed excellent solubility in water. However, as aqueous solutions of AP 5280 proved to be labile upon sterilization by moist heat, it was decided to develop a lyophilized dosage form. Initially, glass vials were used as primary packaging, but this led to a high breakage rate, which could be completely prevented by the use of CZ resin vials. Stability studies to date show that the lyophilized product in glass vials is stable for at least 12 months when stored at 2-8 degrees C in the dark and the lyophilized product in CZ resin vials is stable for at least 6 months under these conditions. Photostability testing revealed photolability of AP 5280 drug substance and lyophilized product in both types of primary container, necessitating storage in the dark. The first clinical experiences indicate that the proposed formulation is fully applicable for use in the clinical setting.
PMID: 14606662 [PubMed - indexed for MEDLINE]